Subscribe To Our Free Newsletter |
No change in 30% EBITDA margin guidance or long-term investment plan: Jonathan Hunt, Syngene
Syngene International, led by Jonathan Hunt, MD & CEO, remains committed to its long-term investment plans despite a guidance cut. The company experienced a slight softness in Q3 but expects it to be a temporary trend in the US biotech segment due to a slowdown in funding. The EBITDA margin guidance of around 30% remains unchanged, and the company is confident in its strong margin structure. As for capex guidance, the company adjusted it to $60 million for the year, with $40 million already invested and $20 million to be completed in the current quarter.